Bone Net Income from 2010 to 2025

BBLGW Stock  USD 20.20  0.00  0.00%   
Bone Biologics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -7.7 M in 2025. During the period from 2010 to 2025, Bone Biologics Net Loss regression line of quarterly data had r-squared of  0.04 and coefficient of variation of (116.94). View All Fundamentals
 
Net Loss  
First Reported
2013-03-31
Previous Quarter
-783.7 K
Current Value
-941 K
Quarterly Volatility
M
 
Yuan Drop
 
Covid
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 11.4 M, Total Operating Expenses of 4.7 M or Gross Profit of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 1.8 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
  
Check out the analysis of Bone Biologics Correlation against competitors.

Latest Bone Biologics' Net Income Growth Pattern

Below is the plot of the Net Income of Bone Biologics Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bone Biologics Corp financial statement analysis. It represents the amount of money remaining after all of Bone Biologics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bone Biologics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (4.11 M)10 Years Trend
Pretty Stable
   Net Income   
       Timeline  

Bone Net Income Regression Statistics

Arithmetic Mean(5,059,841)
Coefficient Of Variation(116.94)
Mean Deviation4,445,436
Median(3,424,811)
Standard Deviation5,916,754
Sample Variance35T
Range21.7M
R-Value(0.20)
Mean Square Error36T
R-Squared0.04
Significance0.46
Slope(245,802)
Total Sum of Squares525.1T

Bone Net Income History

2025-7.7 M
2024-7.3 M
2023-8.9 M
2022695.9 K
2021-1.6 M
2020-1.8 M
2019-3.4 M

Other Fundumenentals of Bone Biologics Corp

Bone Biologics Net Income component correlations

About Bone Biologics Financial Statements

Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Net Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-4.1 M-4.3 M
Net Loss-7.5 M-7.9 M
Net Loss(4.83)(5.07)
Net Loss(0.54)(0.51)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.